Several possible studies
Story checked
Metformin Linked to Better Motor Function in Parkinson's (opens in a new tab)
medscape.com · 2020-05-29
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Metformin Linked to Better Motor Function in Parkinson's
medscape.com · 2020-05-29
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedResearchers are taking a closer look at whether metformin might convey benefit in patients with both Parkinson's disease and diabetes, and are finding some positive signals.View evidenceHide evidence
As statedpositive signals
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 6Not checkedA small retrospective study showed that patients with Parkinson's disease and diabetes who took metformin performed significantly better on tests of motor and nonmotor function than those who did not.View evidenceHide evidence
As statedsignificantly better
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 6Not checkedThe current retrospective cohort study included 19 de novo Parkinson's disease patients with diabetes from the Parkinson's Progression Markers Initiative cohort, split into metformin users (n=8) and nonusers (n=11).View evidenceHide evidence
As stated19 patients; 8 vs 11
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 6Not checkedCompared with patients not taking metformin, those taking it had significantly better MDS-UPDRS total scores, Benton Judgement of Line Orientation scores, Symbol Digit Modalities Test scores, and Semantic Fluency scores.View evidenceHide evidence
As statedP = .04, .04, .03, and .003
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 6Not checkedThe results suggest a potential protective effect of metformin in Parkinson's disease, but the article says further studies are needed and that the methodology limits the ability to conclude metformin caused the apparent benefit.View evidenceHide evidence
As statedpotential protective effect
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 6Not checkedThe article states that these results do not allow one to conclude that metformin, or any other antidiabetic drug, is efficacious and should be prescribed for the treatment of Parkinson's disease.View evidenceHide evidence
As statednot allow us to conclude
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Europe PMC, Crossref · 15 candidate papers
Glucagon-like peptide-1 receptor agonists and the risk of Parkinson's disease in patients with type 2 diabetes: a systematic review and meta-analysis of large-scale real-world data.
Frontiers in Endocrinology · 2026 · PubMed, Europe PMC
Video-based automated analysis of MDS-UPDRS III parameters in Parkinson disease
2022 · Crossref
Exploring the impacts of type 2 diabetes and metformin use on Parkinson's disease: Mendelian randomization analysis and a national cohort study.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026 · PubMed, Europe PMC
Metformin in Neurodegenerative Diseases: Mechanisms and Therapeutic Implications.
Current Neuropharmacology · 2026 · PubMed
Unified Parkinson’s Disease Rating Scale (UPDRS) and Movement Disorder Society Revision of the UPDRS (MDS-UPDRS)
Rating Scales in Parkinson's Disease · 2012 · Crossref
And 10 more candidates considered.